Temsirolimus (CCI-770, Torisel) Combined With Cetuximab in Cetuximab-Refractory Colorectal Cancer
Status:
Completed
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
In this study, the investigational drug, temsirolimus, will be combined with cetuximab, a
biologic agent used in the treatment of colorectal cancer. Cetuximab in combination with
temsirolimus may be more effective in treating advanced colorectal cancer than cetuximab
alone. The purpose of this research study is to try to define the highest dose of cetuximab
that can be used safely in combination with temsirolimus to treat advanced colorectal cancer
that has progressed through standard therapy.
Phase:
Phase 1
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborators:
Brigham and Women's Hospital Dana-Farber Cancer Institute Wyeth is now a wholly owned subsidiary of Pfizer